• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

立陶宛的肾性贫血控制:当地条件和地方指南的影响

Renal anemia control in Lithuania: influence of local conditions and local guidelines.

作者信息

Ziginskiene Edita, Kuzminskis Vytautas, Petruliene Kristina, Vaiciuniene Ruta, Stankuviene Asta, Bumblyte Inga Arune

机构信息

Department of Nephrology, Medical Academy, Lithuanian University of Health Sciences, Mickeviciaus str. 9, LT-44307 Kaunas, Lithuania ; Nephrological Clinic, Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Eiveniu str. 2, LT-50009 Kaunas, Lithuania.

出版信息

ScientificWorldJournal. 2013 Dec 3;2013:260915. doi: 10.1155/2013/260915. eCollection 2013.

DOI:10.1155/2013/260915
PMID:24367239
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3866792/
Abstract

Erythropoietin stimulating agents had a long haul in Lithuania--we had no epoetin till 1994 and there was no intravenous iron in 2001-2004. The aim of this study was to assess the changes of renal anemia control in hemodialysis patients from early independence of Lithuania till nowadays and to evaluate the link of anemia with hospitalization rates and survival and hemoglobin variability in association with mortality. In December of each year since 1996 all hemodialysis centers have been visited and data has been collected using special questionnaires. The history of renal anemia control in Lithuania was complicated; however, a significant improvement was achieved: 54.7% of hemodialysis patients reached the target hemoglobin; all patients have a possibility of treatment with epoetin and intravenous iron. The involuntary experiment with an intravenous iron occurred in Lithuania because of economic reasons and confirmed the significant role of intravenous iron in the management of renal anemia. Hemoglobin below 100 g/L was associated with a 2.5-fold increase in relative risk of death and 1.7-fold increase in relative risk of hospitalization in Lithuanian hemodialysis patients. Although hemoglobin variability was common in Lithuanian hemodialysis patients, we did not find the association between hemoglobin variability and all-cause mortality in our study.

摘要

促红细胞生成素刺激剂在立陶宛的应用历程漫长——1994年之前我们没有促红细胞生成素,2001年至2004年期间没有静脉铁剂。本研究的目的是评估从立陶宛早期独立至今血液透析患者肾性贫血控制情况的变化,并评估贫血与住院率、生存率以及血红蛋白变异性与死亡率之间的关联。自1996年起,每年12月都会走访所有血液透析中心,并使用专门的问卷收集数据。立陶宛肾性贫血的控制历程较为复杂;然而,已取得显著改善:54.7%的血液透析患者达到了血红蛋白目标值;所有患者都有可能接受促红细胞生成素和静脉铁剂治疗。由于经济原因,立陶宛出现了静脉铁剂的非自愿试验,证实了静脉铁剂在肾性贫血管理中的重要作用。在立陶宛血液透析患者中,血红蛋白低于100 g/L与死亡相对风险增加2.5倍以及住院相对风险增加1.7倍相关。尽管立陶宛血液透析患者中血红蛋白变异性很常见,但在我们的研究中未发现血红蛋白变异性与全因死亡率之间的关联。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75f5/3866792/53fccd5ab4f6/TSWJ2013-260915.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75f5/3866792/4c8fa5d8b704/TSWJ2013-260915.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75f5/3866792/b0d588ccac98/TSWJ2013-260915.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75f5/3866792/8cece34a74e1/TSWJ2013-260915.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75f5/3866792/f99e7539c734/TSWJ2013-260915.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75f5/3866792/53fccd5ab4f6/TSWJ2013-260915.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75f5/3866792/4c8fa5d8b704/TSWJ2013-260915.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75f5/3866792/b0d588ccac98/TSWJ2013-260915.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75f5/3866792/8cece34a74e1/TSWJ2013-260915.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75f5/3866792/f99e7539c734/TSWJ2013-260915.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75f5/3866792/53fccd5ab4f6/TSWJ2013-260915.005.jpg

相似文献

1
Renal anemia control in Lithuania: influence of local conditions and local guidelines.立陶宛的肾性贫血控制:当地条件和地方指南的影响
ScientificWorldJournal. 2013 Dec 3;2013:260915. doi: 10.1155/2013/260915. eCollection 2013.
2
The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data.铁在接受促红细胞生成素α和静脉铁治疗的维持性血液透析患者长期生存中的重要性:对9.5年前瞻性收集数据的分析
BMC Nephrol. 2009 Feb 26;10:6. doi: 10.1186/1471-2369-10-6.
3
Protocol adherence and the ability to achieve target haemoglobin levels in haemodialysis patients.血液透析患者的方案依从性及达到目标血红蛋白水平的能力。
Nephrol Dial Transplant. 2009 Jun;24(6):1956-62. doi: 10.1093/ndt/gfn780. Epub 2009 Jan 28.
4
Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization.在一家大型非营利性透析机构中,贫血管理以及种族与死亡率和住院率的关联
Am J Kidney Dis. 2009 Sep;54(3):498-510. doi: 10.1053/j.ajkd.2009.05.007. Epub 2009 Jul 23.
5
2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.2008年日本透析治疗学会:慢性肾脏病肾性贫血指南
Ther Apher Dial. 2010 Jun;14(3):240-75. doi: 10.1111/j.1744-9987.2010.00836.x.
6
[Opatija study: observation of hemodialysis patients and titration of CERA dose just switched from another erythropoiesis stimulating agent].奥帕蒂亚研究:对血液透析患者的观察以及对刚从另一种促红细胞生成刺激剂转换过来的CERA剂量的滴定
Acta Med Croatica. 2012 Jul;66(3):157-64.
7
Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion.医疗机构血红蛋白浓度对透析患者输血风险的影响。
Am J Kidney Dis. 2014 Jun;63(6):997-1006. doi: 10.1053/j.ajkd.2013.10.052. Epub 2013 Dec 4.
8
Maintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a historical prospective study.维持稳定血液透析患者的目标血红蛋白水平:一项历史前瞻性研究
Kidney Int Suppl. 2008 Dec(111):S82-7. doi: 10.1038/ki.2008.524.
9
Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy.接受促红细胞生成素治疗的无症状性心脏病血液透析患者的血红蛋白目标与输血情况
Clin J Am Soc Nephrol. 2008 Nov;3(6):1669-75. doi: 10.2215/CJN.02100508. Epub 2008 Oct 15.
10
Effect of frequency of intravenous iron administration on hemoglobin variability in maintenance hemodialysis patients.静脉注射铁剂频率对维持性血液透析患者血红蛋白变异性的影响。
Int Urol Nephrol. 2018 Aug;50(8):1511-1518. doi: 10.1007/s11255-018-1916-8. Epub 2018 Jun 26.

引用本文的文献

1
The Impact of CKD Anaemia on Patients: Incidence, Risk Factors, and Clinical Outcomes-A Systematic Literature Review.慢性肾脏病贫血对患者的影响:发病率、危险因素及临床结局——一项系统文献综述
Int J Nephrol. 2020 Jul 1;2020:7692376. doi: 10.1155/2020/7692376. eCollection 2020.

本文引用的文献

1
Medical options to fight mortality in end-stage renal disease: a review of the literature.治疗终末期肾病患者死亡率的医学选择:文献综述。
Nephrol Dial Transplant. 2012 Dec;27(12):4298-307. doi: 10.1093/ndt/gfs400. Epub 2012 Oct 8.
2
Hemoglobin variability does not predict mortality in European hemodialysis patients.血红蛋白变异性与欧洲血液透析患者的死亡率无关。
J Am Soc Nephrol. 2010 Oct;21(10):1765-75. doi: 10.1681/ASN.2009101017. Epub 2010 Aug 26.
3
International trends in erythropoietin use and hemoglobin levels in hemodialysis patients.
国际范围内血液透析患者促红细胞生成素的使用和血红蛋白水平的变化趋势。
Kidney Int. 2010 Jul;78(2):215-23. doi: 10.1038/ki.2010.108. Epub 2010 Apr 28.
4
Hemoglobin level variability: anemia management among variability groups.血红蛋白水平变异性:变异性组中的贫血管理。
Am J Nephrol. 2009;30(6):491-8. doi: 10.1159/000243565. Epub 2009 Sep 29.
5
Assessment of urea removal in haemodialysis and the impact of the European Best Practice Guidelines.
Nephrol Dial Transplant. 2009 Apr;24(4):1267-74. doi: 10.1093/ndt/gfn641. Epub 2008 Nov 27.
6
Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis.静脉注射与口服铁剂补充治疗慢性肾脏病贫血的系统评价和荟萃分析。
Am J Kidney Dis. 2008 Nov;52(5):897-906. doi: 10.1053/j.ajkd.2008.05.033. Epub 2008 Oct 8.
7
Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.蔗糖铁静脉注射用于中国血液透析肾性贫血患者
Blood Purif. 2008;26(2):151-6. doi: 10.1159/000113529. Epub 2008 Jan 22.
8
Hemoglobin level variability: associations with mortality.血红蛋白水平变异性:与死亡率的关联。
Clin J Am Soc Nephrol. 2008 Jan;3(1):133-8. doi: 10.2215/CJN.01610407. Epub 2007 Nov 28.
9
Hemoglobin variability and mortality in ESRD.终末期肾病患者血红蛋白变异性与死亡率
J Am Soc Nephrol. 2007 Dec;18(12):3164-70. doi: 10.1681/ASN.2007010058. Epub 2007 Nov 14.
10
Predictors of congestive heart failure in patients on maintenance hemodialysis.维持性血液透析患者充血性心力衰竭的预测因素
Circ J. 2007 Sep;71(9):1424-9. doi: 10.1253/circj.71.1424.